Table 3.
Interactions of NTBD with AmB against clinical strains in vitro after 48-h incubation. MIC—minimal inhibiting concentration of the compound, ∑FIC—coefficient, which is the sum of partial concentrations inhibiting the growth of the pathogens. The interactions were determined based on the specified ranges: synergy (∑FIC ≤ 0.5), indifferent (∑FIC ≥ 0.5 to 4), antagonism (∑FI C> 4); ** = synergy.
| Strain | Separate Treatment |
Combinatory Treatment NTBD + AmB | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 (µg/mL) of NTBD |
4 (µg/mL) of NTBD |
8 (µg/mL) of NTBD |
16 (µg/mL) of NTBD |
32 (µg/mL) of NTBD |
64 (µg/mL) of NTBD |
|||||||||
| MIC NTBD (µg/mL) |
MIC AmB (µg/mL) | MIC AmB (µg/mL) | ƩFIC | MIC AmB (µg/mL) | ƩFIC | MIC AmB (µg/mL) | ƩFIC | MIC AmB (µg/mL) | ƩFIC | MIC AmB (µg/mL) | ƩFIC | MIC AmB (µg/mL) | ƩFIC | |
|
C. albicans
isolate 40 |
>128 | 0.125 | 0.125 | 1.01 | 0.125 | 1.02 | 0.125 | 1.03 | 0.125 | 1.06 | 0.125 | 1.125 | 0.125 | 1.25 |
| C. parapsilosis isolate 73 | >128 | 0.25 | 0.25 | 1.01 | 0.25 | 1.02 | 0.25 | 1.03 | 0.25 | 1.06 | 0.25 | 1.25 | 0.5 | 2.25 |
|
C. krusei
isolate 39 |
>128 | 0.25 | 0.5 | 2.01 | 0.5 | 2.02 | 0.5 | 2.03 | 0.5 | 2.06 | 0.5 | 1.125 | 0.5 | 2.25 |
| C. glabrata isolate 5 | >128 | 0.125 | 0.125 | 1.01 | 0.125 | 1.02 | 0.125 | 1.03 | 0.125 | 1.06 | 0.125 | 1.125 | 0.125 | 1.25 |